Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVG-2089 in chronic inflammatory demyelinating polyneuropathy
2024-515386-34-00Phase 2Completed
- Sponsor
- Nuvig Therapeutics
- Start
- Apr 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
Phase 2, open-label trial of NVG-2089 in chronic inflammatory demyelinating polyneuropathy (CIDP) (2 cohorts), sponsored by Nuvig Therapeutics. Primary endpoints: Treatment-emergent adverse events and serious adverse events and Clinically significant safety findings. Started Apr 2025; status: completed.
02
Drugs
NVG-2089
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on 2024-515386-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515386-34-00.